AI‑driven discovery firm Earendil Labs granted WuXi XDC a global license to its payload‑linker technology to develop antibody‑drug conjugates (ADCs) against multiple targets, creating an agreement worth up to approximately $885 million including milestones and tiered royalties. WuXi XDC will support CMC and manufacturing via its WuXiTecan‑2 platform while Earendil leads product development and commercialization. The deal marries Earendil’s AI‑driven biologics discovery with WuXi XDC’s payload‑linker and CRDMO capabilities, illustrating continued industry momentum for partnering around next‑generation ADC platforms. ADCs are engineered antibodies that deliver cytotoxic payloads to tumor cells; dual‑payload and linker innovations aim to improve potency and overcome resistance. The pact also follows Earendil’s sizable collaborations with Sanofi, signaling a platform commercialization push.